Related Experiment Video
Updated: Mar 1, 2026
11:01
Imaging-Guided Bioreactor for Generating Bioengineered Airway Tissue
Published on: April 6, 2022
3.1K
A Biocompatible Synthetic Lung Fluid Based on Human Respiratory Tract Lining Fluid Composition
Abhinav Kumar1, Wachirun Terakosolphan1, Mireille Hassoun1
1Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College London, London, SE1 9NH, UK.
Pharmaceutical Research
|June 1, 2017
Summary
A new simulated lung fluid (SLF) mimics human respiratory fluid, showing good biocompatibility and enhanced solubility for inhalation drugs like beclomethasone dipropionate and fluticasone propionate.
Area of Science:
- Pulmonary science
- Biopharmaceutical science
- Drug delivery
Background:
- Accurate simulation of lung fluid is crucial for developing inhaled medicines.
- Existing lung fluid simulants lack biorelevance and comprehensive characterization.
- Understanding the biopharmaceutical properties of inhaled drugs requires physiologically relevant media.
Purpose of the Study:
- To characterize a novel biorelevant simulated lung fluid (SLF).
- To compare SLF with existing lung fluid simulants.
- To assess SLF's suitability for biopharmaceutical assays of inhalation medicines.
Main Methods:
- Cryo-transmission electron microscopy and photon correlation spectroscopy for structural analysis.
- MTT assay, morphometric, and transcriptomic analyses for biocompatibility assessment.
- Solubility and dissolution studies of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).
Main Results:
- SLF demonstrated a colloidal structure with lung fluid-like vesicles.
- SLF showed no adverse effects on A549 alveolar cells, with minor metabolic adaptations.
- Enhanced solubility and dissolution of BDP and FP observed in SLF compared to Gamble's solution.
Conclusions:
- The developed SLF is a biorelevant synthetic simulant for inhalation medicines.
- SLF is suitable for studying the biopharmaceutical properties of inhaled drugs.
- This simulant supports the development of an inhaled biopharmaceutics classification system.
